Wednesday, July 8, 2026

Drug profile · INN

mebendazole

mebendazole (PHARMACY ACTION WORM TREATMENT) is a tubulin inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.

FDA: approved TGA: approved
US status approved
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — mebendazole
US status
approved
Class
Route
ORAL
Patents
0
Programs
1
Data quality
0.84

Quick answer

mebendazole (PHARMACY ACTION WORM TREATMENT) is a tubulin inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN mebendazole
Brand PHARMACY ACTION WORM TREATMENT
Mechanism Tubulin inhibitor
Target Tubulin
Route ORAL
Formulation TABLET, CHEWABLE

Mechanism of action

Tubulin inhibitor

Primary target: Tubulin

Approval history

Authority Status Date
FDA approved
TGA approved

Pipeline programs

  1. Mebendazole Phase 2 · Krystal Biotech Netherlands · Pilomyxoid Astrocytoma

Related & competitor drugs

  1. brentuximab vedotin Antineoplastic and immunomodulating agents (L01)
  2. cabazitaxel Antineoplastic and immunomodulating agents (L01)
  3. colchicine Musculo-skeletal system (M04)
  4. docetaxel Antineoplastic and immunomodulating agents (L01)
  5. paclitaxel Antineoplastic and immunomodulating agents (L01)
  6. vincristine sulfate Tubulin inhibitor

Frequently asked questions

What is mebendazole?

mebendazole (PHARMACY ACTION WORM TREATMENT) is a tubulin inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for mebendazole?

PHARMACY ACTION WORM TREATMENT is a marketed brand name for mebendazole. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of mebendazole?

mebendazole has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.